Immune Checkpoint Inhibitors | Real World Brand Tracker | US | 2019
Immune checkpoint inhibitors continue to revolutionize current oncology treatment. Driven by Decision Resources Group’s in-house oncology experts and robust real-world data capabilities, the Real World Brand Tracker captures U.S. claims data to uncover shifting market dynamics and the impact of events on the immune checkpoint inhibitor space, in order to help refine your oncology brand strategies. We cover every approved immune checkpoint inhibitor for every approved oncology indication and monitor the trends in use and reimbursement dynamics over time.
Questions answered:
- How is the uptake for individual immune checkpoint inhibitor brands changing over time?
- Which brand is winning, and how does that vary by indication?
- How does the dynamic regulatory environment for immune checkpoint inhibitors in the U.S. affect prescribing patterns of currently approved immune checkpoint inhibitors by indication?
- What is the average claim charge for each immune checkpoint inhibitor brand and how much if the claim is paid?
- In which type of facilities are patients receiving immune checkpoint inhibitors?
Related Market Assessment Reports
Report
Pulmonary Hypertension – Current Treatment – Current Treatment: Physician Insights – Pulmonary Arterial Hypertension (US)
Pulmonary arterial hypertension (PAH) treatment in the United States is undergoing notable shifts as physicians increasingly adopt guidelinealigned early combination therapy, driving steady use of…
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
